Merck & Co., Inc. (NYSE:MRK) HOLD
A high-quality franchise at ~14x clean forward earnings, roughly 0.80x its warranted multiple, after a Q2 beat-and-raise — so the medium and long calls are both BUY. Short-term it is a HOLD: the stock pulled back ~5% from its 52-week high on cooling momentum, with no confirmed entry yet. Buy on confirmation; accumulate on weakness.
Merck is one of the world's largest research-driven pharma companies, built around KEYTRUDA — the best-selling medicine in the world, running near 8.4 billion dollars a quarter. The report rates it HOLD short-term, BUY medium and BUY long, at a share price of 128 dollars and 37 cents, as of the 7th of August, 2026 — days after a Q2 beat-and-raise. The whole case turns on one question: can the pipeline and a new subcutaneous KEYTRUDA backfill the 2028 patent cliff.
A high-quality franchise racing a dated cliff
The quality here is real, but capped by concentration. Merck earns clean operating margins near twenty-eight percent and gross margins around seventy-six percent, among the best in large-cap pharma, and converts earnings into heavy free cash. Second-quarter revenue rose five percent to sixteen-point-six billion dollars, ahead of consensus, and KEYTRUDA grew four percent to eight-point-four billion. The catch is concentration: KEYTRUDA is roughly forty to forty-five percent of pharma revenue, and its main US patents expire in twenty twenty-eight. The one encouraging signal is the subcutaneous version, QLEX, which ramped from one hundred twenty-eight million dollars to four hundred sixty-three million in a single quarter — a real lever to carry part of the franchise past the cliff.
NYSE: MRK · Mkt cap ~$317bn · Beta 0.21 · KEYTRUDA US LOE 2028
Cheap on clean earnings
On valuation the reported multiple is a red herring this year. Acquired research charges crush both GAAP and non-GAAP earnings — the second-quarter Terns deal alone took two dollars forty-three a share — so the reported P/E of thirty-six times means nothing. On a clean run-rate of about nine dollars, the shares trade at roughly fourteen-point-three times forward earnings; on the Street's nine-sixty, about thirteen-point-four. Against a warranted multiple of seventeen-point-nine times, that is a ratio of zero-point-eight-zero — squarely in the attractive band. The free-cash-flow yield is around five to six percent and the dividend yields two-point-six-five percent at a comfortable thirty-eight percent clean payout. The consensus target is one hundred forty dollars and sixty-four cents, with a median of one forty-six.
Warranted P/E 17.9x vs 14.3x actual · Clean PEG ~2.4 · 68% of analysts bullish
Why the short call is a hold
So why not buy today. The reason is timing, not the business. The primary trend is unambiguously up — every timeframe is in an uptrend and the daily is a strong uptrend above a rising fifty-day average. But the stock ran to a fifty-two-week high of one hundred thirty-five dollars on the twenty-seventh of July and has since pulled back about five percent to one twenty-eight, the daily RSI cooled to the low fifties and the MACD histogram rolled slightly negative. The post-Q2 reaction was flat — a mild sell-the-news. The fundamental entry path is met, but neither the technical nor the catalyst path is, so the entry ladder reads wait and conviction is only half-size. The plan is to buy on confirmation — a volume-backed reclaim of one hundred thirty-two — or on a pullback into the fifty-day average near one twenty-four.
What could go wrong
The risks are real, and they are the reason the bear case exists. That bear sees the shares fall to about one hundred eight dollars, roughly sixteen percent below today, and it is a fat left tail rather than a tail-risk footnote. The core threat is the twenty twenty-eight KEYTRUDA cliff: with the drug at forty to forty-five percent of pharma revenue and seven-plus biosimilar filers waiting at the patent expiry, a sharp share loss is expected from twenty twenty-eight. On top of that, a next-generation rival, ivonescimab from Summit and Akeso, is gaining mind-share in first-line lung-cancer data and could displace KEYTRUDA in key indications. Drug-pricing pressure under the Medicare negotiation rules is a standing overhang on the whole group. And low growth is the honest offset to the low multiple — the clean PEG is about two-point-four. If erosion outpaces the pipeline and the subcutaneous backfill, the driver flips to headwind and the thesis breaks.
Risk vs Reward
The base case is one hundred forty-three dollars at fifty percent — the beat-and-raise trajectory continues, clean earnings hold around nine to nine-sixty, and the market pays roughly fifteen times, in line with consensus. The bull case is one hundred fifty-five at twenty-five percent, about twenty-one percent above today, if QLEX clearly extends the franchise past the cliff, the pipeline delivers, and the multiple re-rates toward sixteen or seventeen times. The bear case is one hundred eight at twenty-five percent, about sixteen percent below, if biosimilar and ivonescimab fears intensify or guidance disappoints. The probability-weighted fair value is about one hundred thirty-seven dollars — a touch above spot, roughly symmetric around a base that already sits above the price. The reward edge is modest; the cliff is the fat left tail.
The verdict
The honest read is a hold now, a buy for the longer run. Merck is a genuinely high-quality oncology and vaccine franchise at about fourteen times clean forward earnings, roughly zero-point-eight-zero times its warranted multiple, after a Q2 beat-and-raise — which is why the medium and long calls are both buy. But the short-term stance is hold: the stock pulled back about five percent from its fifty-two-week high, near-term momentum is cooling, and there is no confirmed technical entry. The plan is to buy on confirmation, or accumulate on weakness — not to chase it, and always mindful of the twenty twenty-eight cliff. This is analysis, not financial advice.
That's my read on Merck. Financial Freedom. Together.
Read the full report on donatien.ca →
